» Articles » PMID: 16211222

Cellular Retinoic Acid-binding Protein 2 is Down-regulated in Prostate Cancer

Overview
Journal Int J Oncol
Specialty Oncology
Date 2005 Oct 8
PMID 16211222
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer is among the most frequent tumours in industrialized nations and many questions remain open concerning the molecular events underlying its development and progression. In the present study we have combined cDNA array hybridization to laser-assisted microdissection (LAM) in order to investigate differences in gene expression between epithelial and stromal cells of prostate cancer and normal peripheral prostate tissue. Results have been verified for selected candidate genes by quantitative real-time RT-PCR. Using this approach and immunohistochemistry we could demonstrate a down-regulation of cellular retinoic acid binding protein 2 (CRABP2) mRNA and protein in carcinoma cells compared to normal glandular cells. CRABP2 is a main regulator of anti-carcinogenic activities of retinoic acid and may become a novel diagnostic marker and experimental therapeutic tool for prostate cancer. In addition, results of cDNA array hybridization suggest an up-regulation of 34 further genes and a down-regulation of 6 genes in cancer tissues compared to normal peripheral prostate tissues. Several of these genes have already been reported to be associated with carcinogenesis in organs such as the prostate.

Citing Articles

Krüppel-like transcription factor 16 transcriptional up-regulation of cellular retinoic acid-binding proteins-2 promotes the invasion and migration and inhibits apoptosis of retinoblastoma cells by regulating integrin-β1/focal adhesion kinase....

Ye L, Liu R, Lin P, Wang W Bioengineered. 2022; 13(2):3694-3706.

PMID: 35671035 PMC: 8973949. DOI: 10.1080/21655979.2021.2024977.


LINC01816 promotes the migration, invasion and epithelial‑mesenchymal transition of thyroid carcinoma cells by sponging miR‑34c‑5p and regulating CRABP2 expression levels.

Zhao H, Zhu X, Luo Y, Liu S, Wu W, Zhang L Oncol Rep. 2021; 45(5).

PMID: 33786631 PMC: 8025121. DOI: 10.3892/or.2021.8032.


APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.

Sogaard C, Moestue S, Rye M, Kim J, Nepal A, Liabakk N Oncotarget. 2018; 9(14):11752-11766.

PMID: 29545934 PMC: 5837745. DOI: 10.18632/oncotarget.24357.


CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression.

Yu S, Parameswaran N, Li M, Wang Y, Jackson M, Liu H Oncotarget. 2017; 8(32):52432-52444.

PMID: 28881741 PMC: 5581040. DOI: 10.18632/oncotarget.14194.


Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases.

Napoli J Pharmacol Ther. 2017; 173:19-33.

PMID: 28132904 PMC: 5408321. DOI: 10.1016/j.pharmthera.2017.01.004.